Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 1.00 |
| ▸ | CD44 | P16070 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.54 |
| ▸ | PRCP | P42785 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 1.00 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 1.00 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11213530 | 0.97 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL20524019 | 0.97 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL987515 | 0.97 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4243903 | 0.97 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5411332 | 0.97 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL2082936 | 0.97 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6635293 | 0.97 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL11838922 | 0.97 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1018 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059959-A | Synthesis method and application of pyrrolo [2,1-a ] isoquinoline compound | 河南工业大学 | 2026-05-19 | — | — | CN | claimed |
| CN-122011028-A | Method for efficiently preparing various substituted chiral phosphoramides | 上海交通大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4658655-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | claimed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| CN-120118077-A | Compound and application thereof | 润尔眼科药物（广州）有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-119948021-A | Nitrogen-containing heterocyclic derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-115872825-B | Preparation method of 1, 3-disubstituted diene compound based on gold carbene catalytic system under room temperature condition | 中国科学院上海有机化学研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-119685868-A | High-activity gamma-Ni (Co) OOH catalyst, preparation method thereof and surface in-situ cleaning method | 安徽大学 | 2025-03-25 | — | — | CN | claimed |
| CN-112876470-B | Method for synthesizing quinazolinone compound under nonmetal catalysis without additive | 中国科学院大连化学物理研究所 | 2022-08-30 | — | — | CN | claimed |
| CN-111465623-B | Active energy ray-curable composition | 学校法人东京理科大学 | 2022-08-02 | — | — | CN | claimed |
| CN-114728918-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-113024458-B | Method for realizing oxidative dehydrogenation of nitrogen-containing heterocycle by biomass-based carbon material | 中国科学院大连化学物理研究所 | 2022-06-07 | — | — | CN | claimed |
| CN-114539144-A | Tetrahydroisoquinoline aryl urea compound and preparation method and application thereof | 蚌埠医学院 | 2022-05-27 | — | — | CN | claimed |
| CN-114516641-A | Mordenite molecular sieve and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2022-05-20 | — | — | CN | claimed |
| WO-2022084446-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2022-04-28 | — | — | WO | claimed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | claimed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| CN-111621805-B | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2022-02-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | PNMT 23/4885CD44 4365/4885MAOB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.